Wellington Management Group
TRDA icon

Wellington Management Group’s Entrada Therapeutics TRDA Stock Holding History

Wellington Management Group’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.02M Sell
954,419
-80,363
-8% -$771K ﹤0.01% 1388
2026
Q1 		$13.1M Sell
1,034,782
-9,976
-1% -$114K ﹤0.01% 1169
2025
Q4 		$10.7M Buy
1,044,758
+90,339
+9% +$761K ﹤0.01% 1236
2025
Q3 		$5.54M Sell
954,419
-106,297
-10% -$622K ﹤0.01% 1417
2025
Q2 		$7.13M Buy
1,060,716
+7,402
+0.7% +$59.6K ﹤0.01% 1300
2025
Q1 		$9.52M Buy
1,053,314
+21,488
+2% +$268K ﹤0.01% 1211
2024
Q4 		$17.8M Buy
1,031,826
+2,457
+0.2% +$44.5K ﹤0.01% 1008
2024
Q3 		$16.4M Sell
1,029,369
-4,558
-0.4% -$71.8K ﹤0.01% 1015
2024
Q2 		$14.7M Buy
1,033,927
+7,087
+0.7% +$101K ﹤0.01% 1034
2024
Q1 		$14.6M Sell
1,026,840
-20,940
-2% -$296K ﹤0.01% 1021
2023
Q4 		$15.8M Buy
1,047,780
+2,128
+0.2% +$31.5K ﹤0.01% 1000
2023
Q3 		$16.5M Buy
1,045,652
+26,144
+3% +$412K ﹤0.01% 975
2023
Q2 		$15.4M Buy
1,019,508
+5,055
+0.5% +$69.6K ﹤0.01% 1005
2023
Q1 		$14.7M Buy
1,014,453
+4,102
+0.4% +$54.8K ﹤0.01% 1008
2022
Q4 		$13.7M Buy
1,010,351
+3,105
+0.3% +$54.4K ﹤0.01% 1003
2022
Q3 		$15.9M Sell
1,007,246
-528,637
-34% -$6.71M ﹤0.01% 980
2022
Q2 		$18.7M Sell
1,535,883
-1,007,219
-40% -$7.64M ﹤0.01% 959
2022
Q1 		$23.8M Sell
2,543,102
-570,904
-18% -$6.12M ﹤0.01% 977
2021
Q4 		$52.8M Buy
+3,114,006
New +$75.5M 0.01% 799

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group's TRDA Position: Q2 2026 in Review

Wellington Management Group reduced its Entrada Therapeutics (TRDA) stake by 7.8% in Q2 2026, selling an estimated $771K and leaving 954,419 shares worth $7.02M. The position accounts for ﹤0.01% of the portfolio, ranked #1388.

Wellington Management Group first reported a position in TRDA in Q4 2021 and has held it in 19 quarters since. The position peaked at $52.8M in Q4 2021. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Wellington Management Group held 954,419 shares of Entrada Therapeutics worth $7.02M as of Q2 2026.
  • Wellington Management Group sold 80,363 Entrada Therapeutics shares in Q2 2026, an estimated $771K.
  • Entrada Therapeutics made up ﹤0.01% of Wellington Management Group's portfolio in Q2 2026, its #1388 holding.
  • Wellington Management Group first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • Wellington Management Group's Entrada Therapeutics position peaked at $52.8M in Q4 2021.
  • 129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.